Alice Berger, Jannie Pedersen, Monika M Kowatsch, Florine Scholte, Marc-Alexandre Lafrance, Hiva Azizi, Yue Li, Alejandro Gomez, Matthew Wade, Hugues Fausther-Bovendo, Marc-Antoine de La Vega, Joseph Jelinski, George Babuadze, Marie-Edith Nepveu-Traversy, Claude Lamarre, Trina Racine, Chil-Yong Kang, Bruno Gaillet, Alain Garnier, Rénald Gilbert, Amine Kamen, Xiao-Jian Yao, Keith R Fowke, Eric Arts, Gary Kobinger
Currently, no effective vaccine to prevent human immunodeficiency virus (HIV) infection is available, and various platforms are being examined. The vesicular stomatitis virus (VSV) vaccine vehicle can induce robust humoral and cell-mediated immune responses, making it a suitable candidate for the development of an HIV vaccine. Here, we analyze the protective immunological impacts of recombinant VSV vaccine vectors that express chimeric HIV Envelope proteins (Env) in rhesus macaques. To improve the immunogenicity of these VSV-HIV Env vaccine candidates, we generated chimeric Envs containing the transmembrane and cytoplasmic tail of the simian immunodeficiency virus (SIV), which increases surface Env on the particle...
March 29, 2024: Vaccines